SynthesisHuman vaccines & immunotherapeutics2026
RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.
Synthesis in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection and hospitalization in infants and young children worldwide. Clinical management in infants remains primarily supportive, and natural infection provides incomplete and transient immunity. For decades, prophylaxis was limited to monthly palivizumab for selected high-risk infants. Recent advances in prefusion F structural biology, antibody engineering, and maternal immunization have transformed RSV prevention. This review summarizes the biologic and clinical rationale for preventing RSV disease in pediatric populations, with emphasis on currently licensed long-acting monoclonal antibodies and maternal RSVpreF vaccination. We integrate a meta-analysis of real-world effectiveness data and discuss implementation of these novel immunoprophylactic strategies in clinical practice. Across 43 observational studies, pooled effectiveness against RSV-associated hospitalization was 80.9% for nirsevimab and 79.1% for maternal RSVpreF vaccination, demonstrating substantial real-world protection during early infancy. Success now depends on optimizing implementation and achieving equitable access.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.